相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2012)
Linagliptin: a novel dipeptidyl peptidase 4 inhibitor with a unique place in therapy
Anthony H. Barnett
ADVANCES IN THERAPY (2011)
Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase
Marjolein J. Willemen et al.
DIABETES CARE (2011)
Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
M. -R. Taskinen et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin
U. Graefe-Mody et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study
R. Gomis et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
S. Del Prato et al.
DIABETES OBESITY & METABOLISM (2011)
Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study
D. R. Owens et al.
DIABETIC MEDICINE (2011)
Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1-Based Therapies
Michael Elashoff et al.
GASTROENTEROLOGY (2011)
Dipeptidylpeptitase-4 Inhibitors (Gliptins) Focus on Drug-Drug Interactions
Andre J. Scheen
CLINICAL PHARMACOKINETICS (2010)
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Rajesh Garg et al.
DIABETES CARE (2010)
Weighing Risks and Benefits of Liraglutide -- The FDA's Review of a New Antidiabetic Therapy.
Mary Parks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
M. Monami et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Advances in therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
J. A. DAVIDSON
CLEVELAND CLINIC JOURNAL OF MEDICINE (2009)
Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide
David D. Dore et al.
CURRENT MEDICAL RESEARCH AND OPINION (2009)
Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus
J. Rosenstock et al.
DIABETES OBESITY & METABOLISM (2009)
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Steven E. Kahn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
DPP-4 inhibitors and their potential role in the management of type 2 diabetes
A. Barnett
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2006)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)